Join a study exploring a new class of investigational medication
Alzheimer's disease (AD aged 55 years of age or older)
Schizophrenia (SCZ aged 18-65)
Major Depressive Disorder (MDD aged 18-65)
Bipolar I or II disorder (BD-I or BD-II aged 18-65)
Generalized Anxiety Disorder (GAD aged 18-65)
Bipolar Depression (aged 18-65)
Major Depressive Disorder (MDD aged 18-65)
Irritable Bowel Syndrome with Constipation (IBS-C aged 12-17)
Bipolar I disorder (BD-I aged 10-17)
Alzheimer's Disease (AD aged 55-90)
Bipolar I or II disorder (BD-I or BD-II aged 18-65)
Alzheimer's Disease (AD aged 55-90)
Alzheimer's Disease (AD aged 55 years of age or older)
Migraine Disorder (aged 6-17)
Migraine Disorder (aged 6-17)
Postpartum Depression (PPD aged 15-45)
Migraine (aged 12-17)
Major Depressive Disorder (MDD aged 18-65)
Bipolar I Disorder (BD-I aged 18-65)
Migraine Disorder (aged 6-17)
Covid-19 Vaccine (aged 6-23 months)
Generalized Anxiety Disorder (GAD aged 18-65)
Alzheimer's Disease (AD aged 55-90)
Bipolar I or Bipolar II Disorder(BD-I or BD-II aged 18-65)
Autism (ASD aged 13-17)
Bipolar I Disorder (BD-I aged 18-75)
Attention-Deficit/Hyperactivity Disorder (ADHD aged 13-17)
Alzheimer's Disease (AD aged 55-85)
Attention-Deficit/Hyperactivity Disorder (ADHD aged 4-5)
Bipolar Disorder (aged 13-17)
Schizophrenia (SCZ at least 18 years old)
Major Depressive Disorder (MDD aged 18-64)
Schizophrenia (SCZ aged 13-17)